Practical Biostatistics

Screening for lung cancer

Author and Disclosure Information

 

In one of our previous articles, we discussed a study of screening for prostate cancer.1 Now we’re going to move up a bit, at least anatomically, and discuss a study of screening for lung cancer.2 We have previously defined ourselves as curmudgeons and skeptics; to those self-descriptions we now add a new term, “chutzpahniks.” For those of you who may be unfamiliar with that Yiddish term, it means people who have chutzpah, which was defined by Leo Rosten3 as: “that quality enshrined in a man who, having killed his mother and father, throws himself on the mercy of the court because he is an orphan.” Our chutzpah stems from the fact that we are criticizing the results of a study that was published in the New England Journal of Medicine and highly praised in an editorial in that journal.4 If we had less chutzpah, we wouldn’t contemplate such a critique, but then again, if we had less chutzpah, we—a clinical psychologist and a nuclear physicist—wouldn’t be writing articles in a cancer journal. So, on to the study...

To read the full article, click on the PDF icon above.

Recommended Reading

No Lung Damage Seen in Typical Marijuana Smokers
MDedge Hematology and Oncology
REVIEW: Comprehensive Management of Respiratory Symptoms in Patients with Advanced Lung Cancer
MDedge Hematology and Oncology
PEER VIEWPOINT: Targeting the Symptoms of Lung Cancer, Not Just the Disease
MDedge Hematology and Oncology
PEER VIEWPOINT: Respiratory Symptoms in Advanced Lung Cancer: A Persistent Challenge
MDedge Hematology and Oncology
Biomarkers May Improve Lung Cancer Screening
MDedge Hematology and Oncology
ASCO Urges Early Palliative Care in Metastatic Cancers
MDedge Hematology and Oncology
Postop Radiation Does Little for Elderly Lung Cancer Patients
MDedge Hematology and Oncology
NICE Decision on Erlotinib to Hinge on Cost Comparison With Gefitinib
MDedge Hematology and Oncology
FDA Tracks Fake Avastin to Foreign Supply Distributed in U.S.
MDedge Hematology and Oncology
VEGF-Targeting Cancer Drugs Raise Risk of Fatal Side Effects
MDedge Hematology and Oncology